The Patent Finder

Bio-Products & Bio-Engineering Aktiengesellschaft

Also on record
Records under this name other than patents Bio-Products & Bio-Engineering Aktiengesellschaft holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 10 of 10 · Back to Bio-Products & Bio-Engineering Aktiengesellschaft

PatentTitleStatus Expires Confidence
US 8,889,624Thrombin-free composition containing freeze-dried, virally inactivated FXIa and serpins and/or kininogen
Lapsed on the fee record
Ended Nov 18, 2022 · From the USPTO record
Lapsed on the fee recordEnded Nov 18, 2022From the USPTO record
US 7,795,399Stable therapeutic proteins
Lapsed on the fee record
Ended Sep 14, 2022 · From the USPTO record
Lapsed on the fee recordEnded Sep 14, 2022From the USPTO record
US 10,047,342Elutriation chamber for an elutriator system
Lapsed on the fee record
Ended Aug 14, 2022 · From the USPTO record
Lapsed on the fee recordEnded Aug 14, 2022From the USPTO record
US 8,741,846Storage-stable, functionally intact fibrinogen
Lapsed on the fee record
Ended Jun 3, 2022 · From the USPTO record
Lapsed on the fee recordEnded Jun 3, 2022From the USPTO record
US 7,494,971Pharmaceutical preparations and medicines capable of generating, and/or containing, thrombin
Lapsed on the fee record
Ended Feb 24, 2021 · From the USPTO record
Lapsed on the fee recordEnded Feb 24, 2021From the USPTO record
US 8,268,362Medicinal product for the promotion of wound healing
Lapsed on the fee record
Ended Sep 18, 2020 · From the USPTO record
Lapsed on the fee recordEnded Sep 18, 2020From the USPTO record
US 7,371,722Pharmaceutical preparations and medicine capable of generating and/or containing thrombin
Lapsed on the fee record
Ended May 13, 2020 · From the USPTO record
Lapsed on the fee recordEnded May 13, 2020From the USPTO record
US 6,372,221Immunogenic constructs comprising flaviviruses or flavivirus derivatives
Term ended
Term ended Dec 12, 2017 · From the USPTO record
Term endedTerm ended Dec 12, 2017From the USPTO record
US 6,034,222Method for the separation of recombinant pro-factor IX from recombinant factor IX
Term ended
Term ended Oct 4, 2015 · From the USPTO record
Term endedTerm ended Oct 4, 2015From the USPTO record
US 5,895,653Adjuvant based on colloidal iron compounds
Term ended
Term ended no later than Apr 20, 2019 · Low confidence
Term endedTerm ended no later than Apr 20, 2019Low confidence
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited